Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 07/30 04:00:26 pm
64.46 USD   -0.66%
07/30DJAstraZeneca Boosted by Licensing Deals -- 2nd Update
07/30DJAstraZeneca Boosted by Licensing Deals -- Update
07/30DJAstraZeneca Boosted by Licensing Deals
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : Reported that European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for...

07/31/2015 | 04:15am US/Eastern

Bristol-Myers Squibb Reported that European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti

Bristol-Myers Squibb Company and AbbVie reported the European Medicines Agency (EMA) validated for review the Marketing Authorization Application (MAA) for Empliciti, an investigational Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in adult patients who have received one or more prior therapies.

The application was granted accelerated assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP).

According to a media release, Bristol-Myers Squibb and AbbVie are co-developing Empliciti, with Bristol-Myers Squibb solely responsible for commercial activities. Bristol-Myers Squibb has proposed the name Empliciti which, if approved by health authorities, will serve as the trade name for elotuzumab.

"The MAA validation marks a significant milestone in Bristol- Myers Squibb's mission to advance the science and impact the treatment of hematologic malignancies through our Immuno-Oncology leadership," said Michael Giordano, MD, senior vice president, head of Oncology Development, Bristol-Myers Squibb. "We believe the CHMP's acceptance for an accelerated assessment reflects the need for a new treatment option for multiple myeloma, a largely incurable disease. We are proud to be one step closer to bringing Empliciti to patients with relapsed or refractory multiple myeloma in Europe."

The MAA is primarily supported by data from two randomized clinical trials, each combining Empliciti with a different standard of care regimen for multiple myeloma. ELOQUENT-2, a Phase 3, randomized, open-label study, evaluated Empliciti in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone. The results of this trial were published in The New England Journal of Medicine on June 2. Additionally, a Phase 2, randomized, open-label study (Study CA004-009) evaluated Empliciti with bortezomib and dexamethasone versus bortezomib and dexamethasone alone. These Phase 2 results were presented in an oral session (Abstract #S103) at the 20th Congress of the European Hematology Association (EHA).

Empliciti previously obtained orphan drug designation in the European Union (EU). An orphan medicinal product must be intended for the treatment, prevention or diagnosis of a disease that is life threatening and chronically debilitating; the prevalence in the EU must not be more than five in 10,000. The medicine must be of significant benefit to those affected by the condition. If maintained, orphan drug designation allows sponsors to access a number of incentives including protocol assistance and receive market exclusivity for a ten-year period following approval.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver medicines that help patients prevail over serious diseases.

AbbVie is a global, research-based biopharmaceutical company.

More Information:

http://www.bms.com

http://www.abbvie.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))

(c) 2015 ProQuest Information and Learning Company; All Rights Reserved., source Trade Publications

React to this article
Latest news on BRISTOL-MYERS SQUIBB CO
04:15a BRISTOL MYERS SQUIBB : Reported that European Medicines Agency Validates and Gra..
07/30 BRISTOL MYERS SQUIBB : European Commission Approves Nivolumab BMS, the First PD-..
07/30DJAstraZeneca Boosted by Licensing Deals -- 2nd Update
07/30DJAstraZeneca Boosted by Licensing Deals -- Update
07/30 BRISTOL MYERS SQUIBB : Reported that European Medicines Agency Validates and Gra..
07/30DJAstraZeneca Boosted by Licensing Deals
07/29 Kyowa Hakko Kirin, Bristol-Myers Announce Immuno-Oncology Clinical Collaborat..
07/29 BRISTOL MYERS SQUIBB : Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immun..
07/29 BRISTOL MYERS SQUIBB : New Pharmaceutical Research Study Findings Recently Were ..
07/29 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Yields New Findings on..
Advertisement
Chart
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Income Statement Evolution
More Financials